Vertex Pharmaceuticals | VRTX - Market Capitalization


Vertex Pharmaceuticals reported $144.23B in Market Capitalization this October of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
AbbVie USD 521.8B 77.2B Oct/2026
Acadia Pharmaceuticals USD 4.33B 537M Jun/2026
Alnylam Pharmaceuticals USD 22.44B 10.57B Oct/2026
Amgen USD 195.44B 5.55B Jun/2026
Arrowhead Research USD 11.5B 2.72B Jun/2026
Biogen USD 35.56B 2.19B Oct/2026
BioMarin Pharmaceutical USD 11.06B 196M Jun/2026
Bristol-Myers Squibb USD 124.51B 2.96B Oct/2026
Gilead Sciences USD 206.51B 21.7B Oct/2026
Incyte USD 26.22B 1.63B Oct/2026
Insmed USD 16.56B 8.37B Oct/2026
Ionis Pharmaceuticals USD 13.1B 642M Jun/2026
J&J USD 607B 46.61B Oct/2026
Merck USD 370.6B 12.1B Oct/2026
Neurocrine Biosciences USD 16.95B 3.7B Jun/2026
Novartis USD 266.01B 25.42B Oct/2026
Pfizer USD 138.44B 15.37B Jun/2026
PTC Therapeutics USD 4.94B 1.86B Oct/2026
Regeneron Pharmaceuticals USD 100.79B 35.42B Oct/2026
Roche Holding CHF 270B 3.66B Jun/2026
Sanofi EUR 99.83B 8.68B Oct/2026
Sarepta Therapeutics USD 1.9B 388M Jun/2026
Ultragenyx Pharmaceutical USD 3.29B 1.23B Jun/2026
United Therapeutics USD 23B 2.19B Jun/2026
Vertex Pharmaceuticals USD 126.07B 12.49B Jun/2026